<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566666</url>
  </required_header>
  <id_info>
    <org_study_id>SCD-044-19-14</org_study_id>
    <nct_id>NCT04566666</nct_id>
  </id_info>
  <brief_title>To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with&#xD;
      moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to&#xD;
      determine the effect of SCD-044 in subjects with moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) score</measure>
    <time_frame>Week16</time_frame>
    <description>The subjects showing at least 75% improvement in Psoriasis Area and Severity Index score on a scale of 0-4 score. Higher score denotes more severe disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA) score</measure>
    <time_frame>Week 16</time_frame>
    <description>The subjects achieving predefined improvement (0 or 1) in Investigator's Global Assessment (IGA) of disease severity on a scale of 0 to 4 score. 0 indicates clear, while 1 indicates almost clear, while 4 is severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psoriasis Area and Severity Index (PASI) scores</measure>
    <time_frame>Week 52</time_frame>
    <description>The subjects achieving predefined improvement in Psoriasis Area and Severity Index (PASI) on a scale of 0-4 score. Higher score denotes more severe disease activity..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) response rate</measure>
    <time_frame>Week 52</time_frame>
    <description>Psoriasis Area and Severity Index (PASI50, PASI75, PASI90, and PASI100) response rate at Week 12, 16, and 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis symptoms and signs diary (PSSD)</measure>
    <time_frame>Week 52</time_frame>
    <description>At study week 0, 16, and 52; based on 11-item questionnaire, the symptoms and patient-observable signs in psoriasis will be score using 0 to 10 rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 52</time_frame>
    <description>At study week 0, 16, and 52; based on 10-item questionnaire on skin problems (0 to 3 scale). The higher the score, the more quality of life is impaired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA) score</measure>
    <time_frame>Week 52</time_frame>
    <description>The subjects achieving predefined improvement (0 or 1) in Investigator's Global Assessment (IGA) of disease severity on a scale of 0 to 4 score. 0 indicates clear, while 1 indicates almost clear, while 4 is severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body surface area (BSA)</measure>
    <time_frame>Week 52</time_frame>
    <description>At study weeks 0, 16, and 52, the Investigator will assess % BSA affected with psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Severity (PGIS)</measure>
    <time_frame>Week 52</time_frame>
    <description>At study weeks 0, 16, and 52, subjects will be asked to assess their overall impression of disease severity using a scale of None, Mild, Moderate or Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Week 52</time_frame>
    <description>At study weeks 16, and 52, subjects will be asked to assess if there has been a change in clinical status using a 7 point scale (1 to 7). 1 indicating 'very much improvement', while 7 indicating 'very much worse'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic parameter</measure>
    <time_frame>Week 52</time_frame>
    <description>Steady-state maximum plasma concentration (Cmax-ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with adverse events</measure>
    <time_frame>Week 56</time_frame>
    <description>Monitoring (frequency, type, and severity) all the adverse events.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Moderate to Severe Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo of SCD-044 product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of SCD-044 study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD-044 Tablets_Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCD-044 tablets at Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD-044 Tablets_Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCD-044 tablets at Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD-044 Tablets_Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCD-044 tablets at Dose 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of SCD-044 product</description>
    <arm_group_label>Placebo of SCD-044 product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCD-044_Dose 1</intervention_name>
    <description>SCD-044 tablets in Dose 1.</description>
    <arm_group_label>SCD-044 Tablets_Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCD-044_Dose 2</intervention_name>
    <description>SCD-044 tablets in Dose 2</description>
    <arm_group_label>SCD-044 Tablets_Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCD-044_Dose 3</intervention_name>
    <description>SCD-044 in Dose 3</description>
    <arm_group_label>SCD-044 Tablets_Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and non-pregnant non-lactating females with a diagnosis of predominantly plaque&#xD;
             psoriasis for â‰¥ 6 months as determined by subject interview and confirmation of&#xD;
             diagnosis through physical examination by Investigator.&#xD;
&#xD;
          2. Aged at least 18 years.&#xD;
&#xD;
          3. Subjects with no history of active TB or symptoms of TB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with non-plaque forms of psoriasis-like erythrodermic psoriasis, pustular&#xD;
             psoriasis, medication-induced, or medication exacerbated psoriasis or new-onset&#xD;
             guttate psoriasis.&#xD;
&#xD;
          2. Subjects who have anticipated the requirement of topical therapy, phototherapy, or&#xD;
             systemic therapy for psoriasis during the trial.&#xD;
&#xD;
          3. Subjects with history or presence of uveitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head, Clinical development</last_name>
    <phone>+912266455645</phone>
    <email>Clinical.Trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site # 08</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

